Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
The Schall Law Firm Begins Probe Into Claims Against Marinus Pharmaceuticals Inc And Urges Affected Investors To Connect
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Inquiry Into Claims Against Marinus Pharmaceuticals, Inc. And Invites Investors Who Have Suffered Losses To Establish Contact
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
The Schall Law Firm Initiates Investigation Into Allegations Against Marinus Pharmaceuticals Inc And Encourages Investors Who Have Incurred Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
The Schall Law Firm Initiates Investigation Into Allegations Against Marinus Pharmaceuticals, Inc. And Encourages Investors Who Have Incurred Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Monday, Marinus Pharmaceuticals Inc MRNS announced topline results from the Phase 3 RAISE trial evaluating the safety and efficacy of intravenous (IV) ganaxolone for refractory status epilepticus (RSE).
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
Investigation Into Claims Against Marinus Pharmaceuticals, Inc. Is Initiated By The Schall Law Firm And Investors Who Have Suffered Losses Are Encouraged To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
